Trials / Recruiting
RecruitingNCT05657873
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Conditions
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non-small Cell Carcinoma
- NSCLC
- NSCLC Stage IV
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | L-SABR | L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy. |
| BIOLOGICAL | Anti-PD-(L)1 based immunotherapy | Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy |
| DRUG | Platinum based chemotherapy | Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy |
Timeline
- Start date
- 2022-12-09
- Primary completion
- 2026-12-09
- Completion
- 2026-12-09
- First posted
- 2022-12-20
- Last updated
- 2026-03-27
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05657873. Inclusion in this directory is not an endorsement.